Whole Genome Sequencing Market to be Worth $7.17 Billion by 2031
Meticulous Research®—a
leading global market research company, published a research report
titled Whole Genome Sequencing Market Size, Share, Forecast, &
Trends Analysis by Offering (Library Preparation, DNA Extraction) Sequencing
Type (Large, Small, Phased), Technology (SBS, SMRT, Nanopore, Nanoball)
Application, End User – Global Forecast to 2031 According to this latest
publication from Meticulous Research®, the global whole genome
sequencing market is projected to reach $7.17
billion by 2031 at a CAGR of 15.2% from 2024 to 2031.
The growth of this
market can be attributed the declining costs of sequencing, the increasing
prevalence of cancer & genetic disorders, the growing utilization of whole
genome sequencing in disease diagnostics & precision medicine, increasing
pharmaceutical R&D expenditures, improvements in regulatory &
reimbursement scenarios for whole genome sequencing, rising healthcare
expenditures, increasing funding for research activities, the growing need for
the early detection & prevention of diseases, technological advancements in
sequencing products, and government initiatives promoting the use of sequencing
in clinical & research applications.. However, the high costs of whole
genome sequencing consumables, the low chances of identifying positive
actionable mutations for precision medicine, and the ethical & legal issues
related to whole genome sequencing-based diagnosis restrain the market’s
growth.
Furthermore,
increasing applications of whole genome sequencing, government support for
large-scale genomic sequencing projects, and emerging economies are expected to
generate growth opportunities for the players operating in this market.
However, uncertainties in the regulatory landscape, the limited expertise &
sequencing capabilities of small & medium-sized laboratories, the lack of
sequencing professionals in developing countries, and the high capital
investments required for NGS setups are major challenges impacting market
growth..
Key Players
The key players
operating in the whole genome sequencing market are Illumina, Inc. (U.S.),
Thermo Fisher Scientific, Inc. (U.S), QIAGEN N.V. (Netherlands), F. Hoffmann-La
Roche Ltd (Switzerland), PerkinElmer, Inc. (U.S) Agilent Technologies, Inc.
(U.S), Pacific Biosciences of California Inc. (U.S), Danaher Corporation (U.S),
Bio-Rad Laboratories, Inc. (U.S.), Oxford Nanopore Technologies Plc. (U.K),MGI
Tech Co., Ltd. (China), and Beijing Genomics Institute (BGI) (China)
Whole Genome
Sequencing Market: Future Outlook
The global whole
genome sequencing market is segmented by offerings (Consumables [Sample
Preparation Kits & Reagents {Nucleic Acid Extraction & Amplification,
Library Preparation & Target Enrichment, Quality Control, and Other
Consumables} Sequencing Instruments, Software, and Services]), Sequencing Type
(Large whole-genome sequencing, Small whole-genome sequencing, Phased
sequencing, Other whole genome sequencing), Technology (Sequencing by
Synthesis, Ion Semiconductor Sequencing, Single-Molecule Real-Time Sequencing
(SMRT), Nanopore Sequencing, DNA Nanoball (DNB) Sequencing, Other NGS
Technologies), Application (Research and other Applications [Drug Discovery,
Agriculture and Animal Research, and Other Applications], Clinical Applications
[Reproductive Health, Oncology, Infectious Diseases, and Other Clinical
Applications]), End User (Pharmaceutical & Biotechnology Companies,
Hospitals & Diagnostic Laboratories, Academic Institutes & Research
Centers, and Other End Users) and Geography. The study also evaluates industry
competitors and analyzes the market at the global and regional levels.
Among all the
offerings studied in this report in 2024, the consumables segment is expected to account for the largest
share of 70.1% of the whole genome sequencing market. The largest share of the
segment is contributed to the increasing demand from end users for advance
whole genome sequencing solutions, recurring demand for sample preparation
consumables due to increasing research and development expenditure by
pharmaceutical and biotechnology industries, continuous advancements in whole
genome sequencing reagents and kits, target enrichment protocols and associated
consumables are factors contributing to the largest share of the segment.
Among all the
sequencing types studied in this report in 2024, the large whole-genome sequencing segment is
expected to account for the largest share of the whole genome sequencing
market. The largest share of the segment is contributed to the advantages
offered by large whole genome sequencing such as it allows characterization of
any genome, by combining short inserts and longer reads, it provides high
resolution view of the genome which is contributing to the largest share of the
segment.
Among all these
technologies studied in this report, in 2024, the sequencing by synthesis
segment is expected to account for the largest share of 56.5% of the whole
genome sequencing market. The largest share of the segment is attributed to the
cost effectiveness of technology, high throughput, high level data resolution,
and high accuracy, are the factors contributing to the largest share of the
segment.
Among all the
applications studied in this report, in 2024, the research applications segment is expected to account for the
largest share of 67.2% of the whole genome sequencing market. The largest share
of the segment is attributed to the wide use of whole genome sequencing in
research, increasing demand for gene-based medicines, growing investments in
drug research and development activities, and increasing research programs for
personalized medicine.
Among all the end
users studied in this report,
in 2024, the pharmaceutical & biotechnology companies’ segment is expected
to account for the largest share of the whole genome sequencing market.
Biotechnology companies utilize genome sequencing in bioprocess development to
improve the efficiency and yield of bioproduction. Additionally, pharmaceutical
and biotechnology companies are increasing the R&D spending which is
raising the adoption of whole genome sequencing among pharmaceutical &
biotechnology companies. contributing to the largest share of the segment
In 2024, North America
is expected to account for the largest share of 52.1% of the whole genome
sequencing market. North America’s major market share is attributed to the high
implementation of sequencing technologies in the region, favorable government
initiatives for genomics research, high cancer prevalence, and rising adoption
of advanced sequencing technologies sequencing. For instance, In September
2023, National Institutes of Health (NIH) (U.S) provided USD 5.8 million for
creating educational hub for computational genomics and data science.
Download Sample
Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=6069
Key questions
answered in the report-
- Which are the high-growth market segments
in terms of offering, sequencing type, technology, application, end user,
and region/country?
- What was the historical market size for
whole genome sequencing globally?
- What are the market forecasts and
estimates for the period 2024–2031?
- What are the major drivers, restraints,
challenges, opportunities, and trends in the global whole genome
sequencing market?
- Who are the major players in the global
whole genome sequencing market?
- What is the competitive landscape like,
and who are the market leaders in the global whole genome sequencing
market?
- What are the recent developments in the
global whole genome sequencing market?
- What are the different strategies adopted
by the major players in the global whole genome sequencing market?
- What are the geographical trends and high
growth regions/countries?
Contact Us:
Meticulous Research®
Email- sales@meticulousresearch.com
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Comments
Post a Comment